The list of emergency uses of the vaccine, developed in partnership with the Beijing Biologics Institute, is for a two-dose regimen for all adults aged 18 and over, said Tedros Adhanom Ghebreyesus, chief executive of the ‘WHO.
It is the first vaccine of any type made in China to receive emergency use authorization from the WHO. The approval is a signal to countries that the Sinopharm vaccine is safe to use and means the vaccine will be added to the WHO Covax vaccine procurement program.
Alejandro Cravioto, chair of the WHO Strategic Advisory Group of Experts on Immunization, said the group had done “a thorough evaluation” of the vaccine, and there was “sufficient evidence” that it was safe. and reduced cases of severe or symptomatic illness by at least 79 percent.
Preliminary studies of the vaccine have mainly been carried out in China, where the coronavirus has already been contained. Final phase, or phase 3, studies have been carried out in other countries. Sinopharm has a second two-dose coronavirus vaccine, which it developed with the Wuhan Institute of Biologics, which has yet to be approved by the WHO.
The WHO clearance is a victory for Sinopharm, which is the main producer of vaccines for the Chinese domestic market and supplies the majority of vaccines for state-run immunization programs, but has not yet established its vaccine exporter status.
The company did not immediately respond to a request for comment.
China has promised Covid vaccines in developing countries, but the international rollout has been hampered by lingering concerns about its effectiveness as Chinese manufacturers have been slower than Western candidates to release detailed test data.
WHO has noted a relative lack of data in elderly patients, recommending that surveillance studies be undertaken in countries where the vaccine is administered to the elderly.
The jab’s approval means it could be used in countries suffering from devastating waves of Covid, such as India and Brazil, the WHO said.
Mohga Kamal-Yanni, a health policy expert at the People’s Vaccine Alliance, said the approval was “great news for people in developing countries who have been watching people in rich countries for months. get vaccinated while they are left behind The tail ”.
Mariângela Simão, WHO’s deputy director-general for access to medicines, said the approval had the potential to “quickly speed up” access for countries seeking to protect health workers and those at risk. more at risk.